DelveInsight’s, “Eczema Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Eczema pipeline landscape. It covers the Eczema pipeline drug profiles, including Eczema clinical trials and nonclinical stage products. It also covers the Eczema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Eczema Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Eczema clinical trials studies, Eczema NDA approvals (if any), and product development activities comprising the technology, Eczema collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Eczema Pipeline Insight Report
- DelveInsight’s Eczema Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Eczema treatment.
- The leading Eczema Companies includes Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
- Promising Eczema Pipeline Therapies includes Amlitelimab, BX 005, LP 0145, GSK 1070806, AR 100, SCM AGH, SCD-044, BBI 02, Lebrikizumab, Benralizumab, UCB9741, ARQ-151, si-544, KHK-4083, ISB-830, B 244, FURESTEM-AD inj, PUR-0110, UCB-1381, FMX-114, BEN 2293, AMTX 100, Gusacitinib, RPT 193, CC 93538, HY-209, AK 002, CM 326, CM 310, RBN 3143, PF-07242813, Apremilast, EDP 1815, MEDI3506, Etrasimod, CMK 389, FB 825, ATI-1777, BSI 045B, LEO-152020, Rilzabrutinib, SHR0302, PRN-473, BTX-1204A, Q-301, Lebrikizumab, CBP 201, BioLexa, KT 474, KBL 697, and others.
- The Eczema companies and academics are working to assess challenges and seek opportunities that could influence Eczema R&D. The Eczema pipeline therapies under development are focused on novel approaches to treat/improve Eczema.
To explore more information on the latest breakthroughs in the Eczema Pipeline treatment landscape of the report, click here @ Eczema Pipeline Outlook
Eczema Overview
Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection. Eczema is commonly known as the “”itch that rashes”” due to dry skin that leads to a rash as a result of scratching or rubbing. The most important treatment of eczema is skin hydration followed by topical steroids for flare-ups. The lifetime prevalence of atopic dermatitis is about 15-30% in children and 2-10% in adults.
Latest Developmental Activities in the Eczema Treatment Landscape
- In August 2022, UNION therapeutics announced enrollment of the first patient in ADESOS Phase II b study of orismilast MR tablet in patients with atopic dermatitis. The purpose of the study is to identify the appropriate dose regimen for Phase III studies.
- In August 2022, Lynk Pharmaceuticals Co., announced that its innovative drug LNK01004, had been approved by National Medical Products Administration (NMPA) for clinical trials in the treatment of atopic dermatitis (AD).
- In June 2022, ASLAN Pharmaceuticals announced that it had initiated a research collaboration with Dr. Shawn Kwatra and Dr. Madan Kwatra from Duke University Medical Center to investigate the unique role of the IL-13Ra1 subunit, distinct from the role of other pathway components, in Type 2-mediated inflammatory diseases, specifically atopic dermatitis (AD).
- In May 2022, Brickell Biotech, Inc. announced that the first subjects were dosed in the single ascending dose (“SAD”) portion of the Company’s Phase 1 clinical trial evaluating BBI-02 in healthy adult subjects and patients with atopic dermatitis (“AD”).
- In April 2022, Eli Lilly and Company announced that Lebrikizumab Combined with Topical Corticosteroids showed significant improvements in disease severity for Atopic Dermatitis. Lebrikizumab significantly improved several areas of great importance to patients with atopic dermatitis, including skin and itch, in a pivotal combination trial that met all primary and key secondary endpoints
- In February 2022, FDA accepted for priority review the supplemental biologics license application (sBLA) for dupilumab (Dupixent, Regeneron Pharmaceuticals, Sanofi) as an add-on maintenance treatment for children aged 6 months to 5 years with moderate to severe atopic dermatitis (AD).
For further information, refer to the detailed Eczema Unmet Needs, Eczema Market Drivers, and Eczema Market Barriers, click here for Eczema Ongoing Clinical Trial Analysis
Eczema Emerging Drugs Profile
Amlitelimab: Kymab
Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of ‘pro-inflammatory’ effector T cells and promoting expansion of ‘anti-inflammatory’ regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczema.
BX 005: BiomX
BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.
LP 0145: LEO Pharma
LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.
Eczema Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Eczema. The companies which have their Eczema drug candidates in the most advanced stage, i.e. phase II include, LEO Pharma.
Request a sample and discover the recent advances in Eczema Ongoing Clinical Trial Analysis and Medications, click here @ Eczema Treatment Landscape
Scope of the Eczema Pipeline Report
- Coverage- Global
- Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
- Eczema Pipeline Therapies- Amlitelimab, BX 005, LP 0145, GSK 1070806, AR 100, SCM AGH, SCD-044, BBI 02, Lebrikizumab, Benralizumab, UCB9741, ARQ-151, si-544, KHK-4083, ISB-830, B 244, FURESTEM-AD inj, PUR-0110, UCB-1381, FMX-114, BEN 2293, AMTX 100, Gusacitinib, RPT 193, CC 93538, HY-209, AK 002, CM 326, CM 310, RBN 3143, PF-07242813, Apremilast, EDP 1815, MEDI3506, Etrasimod, CMK 389, FB 825, ATI-1777, BSI 045B, LEO-152020, Rilzabrutinib, SHR0302, PRN-473, BTX-1204A, Q-301, Lebrikizumab, CBP 201, BioLexa, KT 474, KBL 697, and others.
- Eczema Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Eczema Market Drivers and Eczema Market Barriers, click here @ Eczema Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Eczema: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Eczema– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Amlitelimab: Kymab
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name : Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Eczema Key Companies
- Eczema Key Products
- Eczema- Unmet Needs
- Eczema- Market Drivers and Barriers
- Eczema- Future Perspectives and Conclusion
- Eczema Analyst Views
- Eczema Key Companies
- Appendix
Got Queries? Find out the related information on Eczema Mergers and acquisitions, Eczema Licensing Activities @ Eczema Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/